1Rambaldi A, Barbui T, Barosi G. From Palliation to Epigenetic Therapy in Myelofibrosis. Hematology (American Society of Hematology Education Program Book), 2008: 83-91.
2Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34^+ cells in myelofibrosis with myeloid metaplasia. Blood, 2001, 98: 3249-3255.
3Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 2006, 108: 1497-1503.
4Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood, 2007, 110: 986-993,.
5Giraudier S, Chagraoui H, Komura E, et al. Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood, 2002, 100: 2932-2940.
6Chagraoui H, Tulliez M, Smayra T, et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood, 2003, 101: 2983-2989.
7Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood, 2006, 107: 4589-4596.
8Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med, 2006, 355: 2452-2466.
9Tefferi A, Lasho TL, Schwager SM, et al. The JAK2 (V617F) tyrosine kinase mutation in myelofibrosis with rnyeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol, 2005, 131: 320-328.
10Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 2006, 107: 2098-2100.
